New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma

Villani, Alessia; Potestio, Luca; Fabbrocini, Gabriella; Scalvenzi, Massimiliano

doi:10.1007/s12325-022-02044-1

Cited by 46 publications

(45 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite BCCs rarely distant metastasizes, some cases may cause severe local aggression including soft tissue, cartilage, and bone. There are various treatment options for BCC including curettage, electrodesiccation, cryosurgery, surgical excision, radiotherapy, photodynamic therapy, and drug therapy with topical chemotherapy, oral, or intralesional injections 2,3 . For the treatment of BCCs, oncological radicality is crucial.…”

Section: Introductionmentioning

confidence: 99%

The effect of dermoscopy in assisting on defining surgical margins of basal cell carcinoma

Chen

Liu

Zhou

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

To investigate the diagnostic value of dermoscopy in defining the tumor margin of basal cell carcinoma (BCC) for the appropriate surgical margin. A total of 107 BCC patients were enrolled for this study. The tumor boundaries were observed by naked eye and dermoscope respectively, and 5 mm outward was used as surgical margin according to the dermoscopy-defined margin. Pathological examinations were performed at 2 mm intervals in the direction previously marked and the effect was assessed accordingly. There were still 16.8% of patients whose visual margin was insufficient to the dermoscopy-detected margin. With 2 mm excision margin from the dermoscopy-guided tumor margin, excision range in 12 patients (11.2%) proved to be inadequate, but only 18 surgical margins (4.2%) in the whole 428 excision margin specimens proved to be tumor-positive. While with 4 mm margin, residual lesion was observed in 2 (0.5%) of 107 BCC patients, and positive margin was found in 2 (0.3%) of 428 margin specimen. There has been no recurrence in our study so far.Dermoscopy is superior to visual inspection for defining BCC tumor margin. Under preoperative dermoscopy detection, a 4 mm excision margin of BCC can achieve a radical resection rate of 98.1%, and 92.3% for a 2 mm excision margin of pigmented BCC.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of dermoscopy in assisting on defining surgical margins of basal cell carcinoma

Chen

Liu

Zhou

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Finally, like advanced basal cell carcinomas, advanced cutaneous squamous cell carcinomas may have high mutational burdens, a feature that correlates with response to immunotherapy. The anti-PD1 agent cemiplimab is active in advanced cutaneous squamous cell cancers and is FDA approved for this indication [ 79 , 93 , 94 ].…”

Section: Discussionmentioning

confidence: 99%

“…Republished from [77] with permission from MDPI (Multidisciplinary Digital Publishing Institute), Barcelona, Spain immunotherapy is also a treatment option for patients with advanced and metastatic BCCs [73,75,76,78]. Currently, cemiplimab-a PD1 inhibitor-is the only FDA-approved immunotherapy agent for Hedgehog inhibitorresistant advanced and metastatic BCCs [74,78,79]. However, there are several reports of other anti-PD1 agents (such as nivolumab or pembrolizumab) that have been successfully used to treat advanced (Figs.…”

Section: Basal Cell Carcinoma (Bcc)mentioning

confidence: 99%

Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology

Cohen

Kurzrock

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Precision dermatology uses individualized dermatologic disease-directed targeted therapy (D 3 T 2 ) for the management of dermatoses and for the evaluation and therapy of cutaneous malignancies. Personalized/precision strategies are based on biomarkers that are most frequently derived from tissue transcriptomic expression or genomic sequencing or from circulating cytokines. For instance, the pathologic diagnosis of a pigmented lesion and determining the prognosis of a malignant melanocytic neoplasm can be enhanced by genomic/transcriptomic analysis. In addition to biopsy, innovative techniques have been developed for

show abstract

“…3 Future perspective PD-1/PD-L1 antibodies are generally approved for NSCLC and can be used in clinical practice in Japan as well as in the US and EU, except for cemiplimab. However, in solid tumors other than NSCLC, pembrolizumab for cervical cancer was approved by the FDA in 2018, cemiplimab and pembrolizumab for cSCC in 2018 and 2020, respectively, and cemiplimab for cBCC in 2021; however, none of these agents were approved for in Japan because Japanese patients were not enrolled in pivotal trials (119)(120)(121). In addition, a number of PD-1/PD-L1 antibodies developed in China have not been approved by the PMDA, FDA, or EMA, which is thought to be due in part to the rise of emerging biopharma companies (EBPs)-those with an estimated expenditure on research and development (R&D) of less than $200 million and less than $500 million in revenuewhich contributed more than 70% of the FDA regulatory submission for approval (122,123).…”

Section: Other Novel Immunotherapy Agentsmentioning

confidence: 99%

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

et al. 2022

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC), one of the deadliest types of cancers worldwide, has been the target of immunotherapy due to its high immune antigenicity. With the addition of immune-checkpoint inhibitors (ICIs), including anti-PD-1/PD-L1 antibodies, as an indispensable and powerful regimen for the treatment of this lethal disease, the median survival time for patients with stage IV NSCLC is approximately 2 years. In contrast, the response rate to ICIs remains less than 50%, even if the patients are selected using biomarkers such as PD-L1. Pharmaceutical companies have begun to develop additional anti-PD-1/PD-L1 antibodies to overcome resistance and are devising further immunotherapy combinations. More than 20 anti-PD-1/PD-L1antibodies have been approved or are currently in development. Numerous combination therapies are under development, and several combination therapies have provided positive results in randomized controlled trials. This review aimed to examine the current status of approved and investigational anti-PD-1/PD-L1antibodies for NSCLC in Japan, the United States, the European Union, and China. Further, this review discusses the challenges and future perspectives for developing new ICIs in alignment with the global developments in Japan.

show abstract

New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma

Cited by 46 publications

References 51 publications

The effect of dermoscopy in assisting on defining surgical margins of basal cell carcinoma

The effect of dermoscopy in assisting on defining surgical margins of basal cell carcinoma

Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

Contact Info

Product

Resources

About